Most elderly patients with pancreatic cancer will have poor performance status due to age, comorbidities, renal failure, dementia, and cardiovascular disease, among others, explains Puri. The standard practice is to give these patients FOLFIRINOX as long as they have good performance status, says Puri. Read more . . .
Akshjot Puri, MD, fellow, Houston Methodist Hospital, discusses challenges facing older patients with pancreatic cancer.